Cullinan Oncology, Inc. reported updated data from the Company’s ongoing Phase I/IIa trial of CLN-081 in non-small cell lung cancer patients whose tumors harbor epidermal growth factor receptor exon 20 insertion mutations that have progressed on or after prior therapy.
[Cullinan Oncology, Inc.]
Sorry, but the selected Zotpress account can't be found.
